1003312-16-0

Basic information

• Product Name: 6-(2-(4-methoxybenzyloxy)-4-methylpyridin-3-yl)quinazolin-2-amine
• Synonyms: 6-(2-(4-methoxybenzyloxy)-4-methylpyridin-3-yl)quinazolin-2-amine
• CAS NO: 1003312-16-0
• Molecular Weight: 372.426
• Mol File: 1003312-16-0.mol

Chemical Properties

• CAS DataBase Reference: 6-(2-(4-methoxybenzyloxy)-4-methylpyridin-3-yl)quinazolin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(2-(4-methoxybenzyloxy)-4-methylpyridin-3-yl)quinazolin-2-amine(1003312-16-0)
• EPA Substance Registry System: 6-(2-(4-methoxybenzyloxy)-4-methylpyridin-3-yl)quinazolin-2-amine(1003312-16-0)

Safety Data

• Hazardous Substances Data: 1003312-16-0(Hazardous Substances Data)

Upstream product

• 882670-92-0 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-quinazolin-2-amine 
• 1003312-15-9 2-(4-methoxybenzyloxy)-3-bromo-4-methylpyridine 
• 105-13-5 4-Methoxybenzyl alcohol 
• 55404-31-4 3-bromo-2-chloro-4-methylpyridine 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 

Relevant articles and documents

INHIBITOR OF BRUTON'S TYROSINE KINASE

Disclosed herein is a compound of Formula (I) with a Btk inhibitory activity, wherein all the variables are as defined herein. The compound can be used for the treatment of diseases such as autoimmune diseases, xenogeneic immune diseases, cancers or thromboembolic diseases. Also disclosed is a pharmaceutical composition comprising a compound of Formula (I). Futher provided is a compound capable of inhibiting the activity of Bruton's tyrosine kinase by covalent binding.

Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit

Inhibition of c-Kit has the potential to treat mast cell associated fibrotic diseases. We report the discovery of several aminoquinazoline pyridones that are potent inhibitors of c-Kit with greater than 200-fold selectivity against KDR, p38, Lck, and Src.

SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE

The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula: (I); wherein A0-3 and R1-6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.